Dermatology

Christopher Bunick, MD, PhD, and colleagues conducted a review bispecific and trispecific antibodies in atopic dermatitis.

In this segment of the interview, questions remaining about AI's effectiveness among patients in dermatology were explored.

Liu and Sayres emphasize that while AI tools improve consumer recognition of skin conditions, gaps remain in prediction accuracy and information.

FDA approved dupilumab for children aged 2 to 11 years with chronic spontaneous urticaria uncontrolled by H1 antihistamines.

This interview highlights new data assessing whether artificial intelligence (AI)–powered tools can help consumers better understand dermatology cases.

At the 2026 AAD Annual Meeting, Nambudiri spoke on various points, including how emerging AI tools may help reduce administrative burden in dermatology.

There is an antifungal-resistant dermatophyte spreading globally, and experts are urging clinicians to become more aware.

54-week STOP-HS data show clinically meaningful improvements in pain, fatigue, and quality of life in one-third to two-thirds of patients.

Phase 2b data from the 16-week extension of REZOLVE-AA suggest rezpegaldesleukin leads to continued hair regrowth through 52 weeks.

This interview highlights positive 12-month phase 3 results on clascoterone 5% topical solution for mild-to-moderate androgenetic alopecia, or hair loss.

In a Q&A from AAD 2026, Elmariah highlights a variety of significant results highlighted in a poser session from the RELIEVE-PN study regarding dupilumab for prurigo nodularis.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Blauvelt discusses studies revealing that disease severity, injection frequency, pain, and geography all shape treatment preferences.

Nambudiri discusses the AAD Clinical Image Collection, launched in January 2025 to address the lack of diverse representation in dermatology education.

Extension data through week 54 reveal deepening responses with povorcitinib in moderate-to-severe HS.

This Q&A interview highlights several takeaways from the data on upadacitinib in patients with non-segmental vitiligo (NSV).

HS is associated with up to a nearly 2-fold increased risk of heart failure, coronary artery disease, myocardial infarction, venous thromboembolism, and all-cause mortality.

In this interview from AAD 2026, Glick speaks about key insights on topical steroid withdrawal (TSW) and on the future of dermatology.

The FDA has accepted LEO Pharma's sNDA for delgocitinib cream for moderate-to-severe chronic hand eczema in adolescents.

This phase 2b study on brensocatib did not meet its primary or secondary efficacy endpoints, causing Insmed to discontinue their HS program.

This interview with Stephan Weidinger, MD, PhD, at AAD 2026 highlights new data on lebrikizumab

The combination showed efficacy in a predominantly female, treatment-experienced, high-BMI population.

This Q&A interview from AAD 2026 covers a number of notable tips for clinicians in dermatology regarding topical therapies.

This Q&A interview at AAD 2026 highlights a number of notable tips for clinicians in dermatology from the ‘Pearls: Diagnostic and Therapeutic’ talk.